NCMAG125 Paclitaxel advice document: January 2026
Posted on:
Document Type
NCMAG advice
Process guidance
Summary
Paclitaxel (weekly) in combination with trastuzumab plus pertuzumab for the first-line treatment of adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who are considered fit for treatment with pertuzumab plus trastuzumab plus a taxane. Off label use.
Decision: supported as an alternative option to on-label treatments